Skip to main content
. 2016 Nov 10;5(12):665–673. doi: 10.1002/psp4.12137

Figure 4.

Figure 4

Comparison of model predictions of Tab concentrations (individual predictions and population predictions) for (a) Model 3 vs. Model 2 and (b) Model 4 vs. Model 2, for subjects from the phase II study for pinatuzumab vedotin and polatuzumab vedotin, respectively. Black open circles: each Tab PK data point for subjects from the phase II study; red line: LOESS smooth line.